Please login to your online account to display your discounted pricing

BMI-1 Mouse anti-Human, Clone: AF27, eBioscience™

Mouse Monoclonal Antibody

$172.55 - $448.05

Specifications

Antigen BMI-1
Clone AF27
Host Species Mouse
Species Reactivity Human
Applications Immunocytochemistry
View More Specs

 Disclaimers

For Research Use Only.

Products
Catalog Number Mfr. No. Quantity Price Quantity    

501122802

 
affymetrix
14970280
25μg Each for $172.55

501122803

 
affymetrix
14970282
100μg Each for $448.05
Description & Specifications

Specifications

Antigen BMI-1
Clone AF27
Host Species Mouse
Species Reactivity Human
Applications Immunocytochemistry
Applications Immunohistochemistry (Frozen)
Applications Immunoprecipitation
Applications Microscopy
Regulatory Status RUO
Conjugate Unlabeled
Format Purified
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Concentration 0.5mg/mL

The monoclonal antibody AF27 recognizes human BMI-1 (B cell-specific Moloney murine leukemia virus integration site 1), a member of the polycomb group (PcG) proteins responsible for repression of gene expression through recognition and modification of histone methylation and chromatin structure. BMI-1 contains a ring finger domain, a helix-turn-helix domain necessary for inducing telomerase activity and is a member of the polycomb repressive complex 1 (PRC1). BMI-1 localizes to the nucleus and plays an important role in self-renewal of normal as well as hematopoietic, embryonic, neural, and other stem cell populations through regulation of genes involved in proliferation such as Sox2 and KLF4. Decreased BMI-1 expression is associated with differentiation, while overexpression is frequently found in variety of cancers. BMI-1 has been shown to be essential for epithelial to mesenchymal transition (EMT) in head and neck and breast cancers and elevated BMI-1 expression correlates with poor prognosis in patients with neuroblastoma, glioma, non-Hodgkin B-cell lymphoma, oropharyngeal squamous cell cancer, non-small cell lung cancer, and primary and metastatic melanoma.